Mogamulizumab (Anti-CCR4) in HTLV-1-Associated Myelopathy
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Human T-lymphotropic virus type 1 (HTLV-1) causes the debilitating neuroinflammatory disease HTLV-1-associated myelopathy-tropical spastic paraparesis (HAM-TSP) as well as adult T-cell leukemia-lymphoma (ATLL). In patients with HAM-TSP, HTLV-1 infects mainly CCR4+ T cells and induces functional changes, ultimately causing chronic spinal cord inflammation. We evaluated mogamulizumab, a humanized anti-CCR4 monoclonal antibody that targets infected cells, in patients with HAM-TSP. METHODS: In this uncontrolled, phase 1-2a study, we assessed the safety, pharmacokinetics, and efficacy of mogamulizumab in patients with glucocorticoid-refractory HAM-TSP. In the phase 1 dose-escalation study, 21 patients received a single infusion of mogamulizumab (at doses of 0.003 mg per kilogram of body weight, 0.01 mg per kilogram, 0.03 mg per kilogram, 0.1 mg per kilogram, or 0.3 mg per kilogram) and were observed for 85 days. Of those patients, 19 continued on to the phase 2a study and received infusions, over a period of 24 weeks, of 0.003 mg per kilogram, 0.01 mg per kilogram, or 0.03 mg per kilogram at 8-week intervals or infusions of 0.1 mg per kilogram or 0.3 mg per kilogram at 12-week intervals. RESULTS: The side effects of mogamulizumab did not limit administration up to the maximum dose (0.3 mg per kilogram). The most frequent side effects were grade 1 or 2 rash (in 48% of the patients) and lymphopenia and leukopenia (each in 33%). The dose-dependent reduction in the proviral load in peripheral-blood mononuclear cells (decrease by day 15 of 64.9%; 95% confidence interval [CI], 51.7 to 78.1) and inflammatory markers in cerebrospinal fluid (decrease by day 29 of 37.3% [95% CI, 24.8 to 49.8] in the CXCL10 level and of 21.0% [95% CI, 10.7 to 31.4] in the neopterin level) was maintained with additional infusions throughout the phase 2a study. A reduction in spasticity was noted in 79% of the patients and a decrease in motor disability in 32%. CONCLUSIONS: Mogamulizumab decreased the number of HTLV-1-infected cells and the levels of inflammatory markers. Rash was the chief side effect. The effect of mogamulizumab on clinical HAM-TSP needs to be clarified in future studies. (Funded by the Japan Agency for Medical Research and Development and the Ministry of Health, Labor, and Welfare; UMIN trial number, UMIN000012655 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mogamulizumab targets CCR4, a chemokine receptor highly expressed by HTLV-1-infected T cells [198,199,200], with phase I and II clinical trials resulting in an overall response rate (ORR) of 50% [201,202,203].”
From Current State of Therapeutics for HTLV-1 (2024) · cites this paper as [203]
In the citing paper
“A phase I/IIa clinical trial involving 21 patients also reported its utility for HAM [203]. Mogamulizumab reduced HTLV-1 PVL, cytokine production, and spontaneous proliferation, improved motor ability in 32% of patients, and reduced spasticity in 79% of patients.”
From Current State of Therapeutics for HTLV-1 (2024) · cites this paper as [203]
In the citing paper
“The most notable side effects were rashes, with the serious adverse events lymphopenia and leukopenia reported in 33% of patients each.”
From Current State of Therapeutics for HTLV-1 (2024) · cites this paper as [203]
Citations
Cites
The Timed “Up & Go”: A Test of Basic Functional Mobility for Frail Elderly Persons
Podsiadlo, D., & Richardson, S. (1991) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1991.tb01616.x · Cited by 14,418
Interrater Reliability of a Modified Ashworth Scale of Muscle Spasticity
Bohannon, R. W., & Smith, M. B. (1987) · Physical Therapy · doi:10.1093/ptj/67.2.206 · Cited by 5,424
The American Urological Association Symptom Index for Benign Prostatic Hyperplasia
Barry, M. J., Fowler, F. J., O’Leary, M. P., Bruskewitz, R. C., Holtgrewe, H. L., Mebust, W. K., Cockett, A. T. K., & The Measurement Committee of the American Urological Association (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)36966-5 · Cited by 3,436
ANTIBODIES TO HUMAN T-LYMPHOTROPIC VIRUS TYPE-I IN PATIENTS WITH TROPICAL SPASTIC PARAPARESIS
Gessain, A., Vernant, J. C., Maurs, L., Barin, F., Gout, O., Calender, A., & De Thé, G. (1985) · The Lancet · doi:10.1016/s0140-6736(85)92734-5 · Cited by 2,843
HTLV-I ASSOCIATED MYELOPATHY, A NEW CLINICAL ENTITY
Osame, M., Usuku, K., Izumo, S., Ijichi, N., Amitani, H., Igata, A., Matsumoto, M., & Tara, M. (1986) · The Lancet · doi:10.1016/s0140-6736(86)91298-5 · Cited by 2,404
Adult T-cell leukemia: clinical and hematologic features of 16 cases
Uchiyama, T., Yodoi, J., Sagawa, K., Takatsuki, K., & Uchino, H. (1977) · Blood · doi:10.1182/blood.v50.3.481.481 · Cited by 2,316
Hinuma, Y., Nagata, K., Hanaoka, M., Nakai, M., Matsumoto, T., Kinoshita, K. I., Shirakawa, S., & Miyoshi, I. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.10.6476 · Cited by 2,252
ICIQ: A brief and robust measure for evaluating the symptoms and impact of urinary incontinence
Avery, K., Donovan, J., Peters, T. J., Shaw, C., Gotoh, M., & Abrams, P. (2004) · Neurourology and Urodynamics · doi:10.1002/nau.20041 · Cited by 1,972
Epidemiological Aspects and World Distribution of HTLV-1 Infection
Gessain, A., & Cassar, O. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00388 · Cited by 1,428
Symptom assessment tool for overactive bladder syndrome—overactive bladder symptom score
Homma, Y., Yoshida, M., Seki, N., Yokoyama, O., Kakizaki, H., Gotoh, M., Yamanishi, T., Yamaguchi, O., Takeda, M., & Nishizawa, O. (2006) · Urology · doi:10.1016/j.urology.2006.02.042 · Cited by 764
Research works printed but not linked: 1
- Osame M. Review of WHO Kagoshima Meeting and diagnostic guidelines for HAM/TSP. In: Blattner WA ed. Human retrovirology. New York: Raven Press 1990:191-197.
Cited by
Doi, T., Muro, K., Ishii, H., Kato, T., Tsushima, T., Takenoyama, M., Oizumi, S., Gemmoto, K., Suna, H., Enokitani, K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1090 · Cited by 161
Clinical significance of chemokine receptor antagonists
Miao, M., Clercq, E. D., & Li, G. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1711884 · Cited by 124
CCR4 as a Therapeutic Target for Cancer Immunotherapy
Yoshie, O. (2021) · Cancers · doi:10.3390/cancers13215542 · Cited by 116
Clinical and Public Health Implications of Human T-Lymphotropic Virus Type 1 Infection
Legrand, N., McGregor, S., Bull, R. A., Bajis, S., Valencia, B. M., Ronnachit, A., Einsiedel, L. J., Gessain, A., Kaldor, J. M., & Martinello, M. (2022) · Clinical Microbiology Reviews · doi:10.1128/cmr.00078-21 · Cited by 96
40 years of the human T-cell leukemia virus: past, present, and future
Tagaya, Y., Matsuoka, M., & Gallo, R. C. (2019) · F1000Research · doi:10.12688/f1000research.17479.1 · Cited by 94
Self-citationSarkar, T., Dhar, S., Chakraborty, D., Pati, S., Bose, S., Panda, A. K., Basak, U., Chakraborty, S., Mukherjee, S., Guin, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.740588 · Cited by 82
Hatano, Y., Ideta, T., Hirata, A., Hatano, K., Tomita, H., Okada, H., Shimizu, M., Tanaka, T., & Hara, A. (2021) · Cancers · doi:10.3390/cancers13112625 · Cited by 77
Yamauchi, J., Araya, N., Yagishita, N., Sato, T., & Yamano, Y. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107669 · Cited by 69
Self-citationMaeda, Y., Wada, H., Sugiyama, D., Saito, T., Irie, T., Itahashi, K., Minoura, K., Suzuki, S., Kojima, T., Kakimi, K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27574-0 · Cited by 61
Nozuma, S., & Jacobson, S. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00885 · Cited by 59
Nagasaka, M., Yamagishi, M., Yagishita, N., Araya, N., Kobayashi, S., Makiyama, J., Kubokawa, M., Yamauchi, J., Hasegawa, D., Coler-Reilly, A. L. G., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1920346117 · Cited by 57
Self-citationImmunovirological markers in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)
Enose-Akahata, Y., & Jacobson, S. (2019) · Retrovirology · doi:10.1186/s12977-019-0499-5 · Cited by 49
Nozuma, S., Kubota, R., & Jacobson, S. (2020) · Journal of NeuroVirology · doi:10.1007/s13365-020-00881-w · Cited by 48
Human T-Lymphotropic Virus (HTLV): Epidemiology, Genetic, Pathogenesis, and Future Challenges
Branda, F., Romano, C., Pavia, G., Bilotta, V., Locci, C., Azzena, I., Deplano, I., Pascale, N., Perra, M. T., Giovanetti, M., et al. (2025) · Viruses · doi:10.3390/v17050664 · Cited by 47
Human retroviral antisense mRNAs are retained in the nuclei of infected cells for viral persistence
Ma, G., Yasunaga, J., Shimura, K., Takemoto, K., Watanabe, M., Amano, M., Nakata, H., Liu, B., Zuo, X., & Matsuoka, M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014783118 · Cited by 47
Self-citationThe Role of Chemokines in the Pathogenesis of HTLV-1
Zargari, R., Mahdifar, M., Mohammadi, A., Vahidi, Z., Hassanshahi, G., & Rafatpanah, H. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00421 · Cited by 37
Penova, M., Kawaguchi, S., Yasunaga, J., Kawaguchi, T., Sato, T., Takahashi, M., Shimizu, M., Saito, M., Tsukasaki, K., Nakagawa, M., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004199118 · Cited by 35
Self-citationCurrent Perspectives in Human T-Cell Leukemia Virus Type 1 Infection and Its Associated Diseases
Miura, M., Naito, T., & Saito, M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.867478 · Cited by 34
Human T-cell Leukemia Virus Type 1 and Strongyloides stercoralis: Partners in Pathogenesis
Dykie, A., Wijesinghe, T., Rabson, A. B., Madugula, K., Farinas, C., Wilson, S., Abraham, D., & Jain, P. (2020) · Pathogens · doi:10.3390/pathogens9110904 · Cited by 33
Tamaki, K., Sato, T., Tsugawa, J., Fujioka, S., Yagishita, N., Araya, N., Yamauchi, J., Coler-Reilly, A. L. G., Nagasaka, M., Hasegawa, Y., et al. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02110 · Cited by 29
Self-citationMontalvo, M., & Cho, T. A. (2018) · Neurologic Clinics · doi:10.1016/j.ncl.2018.06.001 · Cited by 29
Suzuki, Y., Saito, M., Ishii, T., Urakawa, I., Matsumoto, A., Masaki, A., Ito, A., Kusumoto, S., Suzuki, S., Hiura, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2575 · Cited by 29
Infections of the Spine and Spinal Cord
Bhattacharyya, S., & Bradshaw, M. J. (2021) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001031 · Cited by 28
Latency Reversing Agents: Kick and Kill of HTLV-1?
Schnell, A. P., Kohrt, S., & Thoma‐Kress, A. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115545 · Cited by 25
Extracellular Vesicles in HTLV-1 Communication: The Story of an Invisible Messenger
Sharif, S. A., Pinto, D. O., Mensah, G. A., Dehbandi, F., Khatkar, P., Kim, Y., Branscome, H., & Kashanchi, F. (2020) · Viruses · doi:10.3390/v12121422 · Cited by 24
Current State of Therapeutics for HTLV-1
Wang, T. T., Hirons, A., Doerflinger, M., Morris, K. V., Ledger, S., Purcell, D. F. J., Kelleher, A. D., & Ahlenstiel, C. L. (2024) · Viruses · doi:10.3390/v16101616 · Cited by 22
“…Topical or systemic corticosteroids and mydriatics [263] HTLV-1-associated Sjögren’s Syndrome Artificial lubricants such as saliva/tears replacement solutions coupled with systemic pharmacotherapy with pilocarpine hydrochloride [264] HTLV-1-associated Hashimoto’s thyroiditis and Graves’ disease”
BackgroundSato, T., Nagai, M., Watanabe, O., Misu, T., Takenouchi, N., Ohkubo, R., Ishihara, S., Tsuboi, Y., Katsuno, M., Nakagawa, M., et al. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12239-x · Cited by 21
Self-citationJinushi, K., Saito, T., Kurose, K., Suzuki, S., Kojima, T., Takahara, T., Makino, T., Ogawa, T., Nishikawa, H., Kakimi, K., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010634 · Cited by 20
Clinical trial of a humanized anti‐IL‐2/IL‐15 receptor β chain in HAM/TSP
Enose‐Akahata, Y., Oh, U., Ohayon, J. M., Billioux, B. J., Massoud, R., Bryant, B. R., Vellucci, A., Ngouth, N., Cortese, I. C. M., Waldmann, T. A., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50820 · Cited by 20
CCL17 acts as an antitumor chemokine in micromilieu‐driven immune skewing
Li, Y., Cao, H., Jiang, Z., Yan, K., Shi, J., Wang, S., Wang, F., Wang, W., Li, X., Sun, N., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110078 · Cited by 20
Saito, M., Ishii, T., Urakawa, I., Matsumoto, A., Masaki, A., Ito, A., Kusumoto, S., Suzuki, S., Takahashi, T., Morita, A., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001641 · Cited by 20
Toledano, M. (2021) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000930 · Cited by 19
CRISPR Genome Editing Applied to the Pathogenic Retrovirus HTLV-1
Panfil, A. R., Green, P. L., & Yoder, K. E. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.580371 · Cited by 17
Saab, L., DiCapua, D. B., & Zubair, A. S. (2024) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2024.122973 · Cited by 16
Altieri, A. D., Reilly, S. P., Mansalay, A., Khoo, A. S. B., Johnson, N., Khan, Z. K., Leader, A. E., Jain, P., & Porcu, P. (2025) · Viruses · doi:10.3390/v17101333 · Cited by 16
Long-term safety and efficacy of mogamulizumab (anti-CCR4) for treating virus-associated myelopathy
Sato, T., Yamauchi, J., Yagishita, N., Araya, N., Takao, N., Ohta, Y., Inoue, E., Takahashi, M., Yamagishi, M., Suzuki, Y., et al. (2023) · Brain · doi:10.1093/brain/awad139 · Cited by 15
Self-citationIdentification and tracking of HTLV-1–infected T cell clones in virus-associated neurologic disease
Nozuma, S., Matsuura, E., Tanaka, M., Kodama, D., Matsuzaki, T., Yoshimura, A., Sakiyama, Y., Nakahata, S., Morishita, K., Enose‐Akahata, Y., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.167422 · Cited by 14
Functional and Pathogenic Roles of Retroviral Antisense Transcripts
Toyoda, K., & Matsuoka, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.875211 · Cited by 14
Self-citationZimmerer, J. M., Ringwald, B. A., Chaudhari, S., Han, J. L., Peterson, C. M., Warren, R. T., Hart, M., Abdel‐Rasoul, M., & Bumgardner, G. L. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100334 · Cited by 14
Wang, S., Jayarangaiah, A., Malone, M. A. V., Elrafei, T. N., Steinberg, L., & Kumar, A. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100601 · Cited by 14
Du, J., Qiu, C., Li, W.-S., Wang, B., Han, X., Lin, S.-W., Fu, X.-H., Hou, J. L., & Huang, Z. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2709270 · Cited by 14
Ghezeldasht, S. A., Mosavat, A., & Rezaee, S. A. (2024) · Reviews in Medical Virology · doi:10.1002/rmv.2567 · Cited by 12
Emerging sexually transmitted viral infections: Review of human T-lymphotropic virus-1 disease
Caswell, R. J., & Manavi, K. (2020) · International Journal of STD & AIDS · doi:10.1177/0956462419886940 · Cited by 12
Ma, G., Yasunaga, J., Ohshima, K., Matsumoto, T., & Matsuoka, M. (2019) · Journal of Virology · doi:10.1128/jvi.00413-19 · Cited by 12
Self-citationIkebe, E., Matsuoka, S., Tezuka, K., Kuramitsu, M., Okuma, K., Nakashima, M., Kobayashi, S., Makiyama, J., Yamagishi, M., Oyadomari, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001139 · Cited by 12
Self-citationZhang, R., Miao, T., Qin, M., Zhao, C., Wang, W., Zhang, C., Liu, X., Chen, Y., Chen, A., & Wang, Y. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.672720 · Cited by 10
HTLV-1-associated myelopathy in Spain
de Mendoza, C., Latorre, L. P., Rando‐Segura, A., Reina, G., Aguilera, A., Benito, R., Bouza, J. M. E., Rodríguez-Avial, I., Ortega, D., Pozuelo, M. J., et al. (2023) · Journal of Clinical Virology · doi:10.1016/j.jcv.2023.105619 · Cited by 10
Fletcher, A. M., & Bhattacharyya, S. (2024) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001393 · Cited by 9
Advances in the treatment of human T-cell lymphotropic virus type-I associated myelopathy
Mashkani, B., Jalili‐Nik, M., Rezaee, S. A., & Boostani, R. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2272639 · Cited by 9
Kodama, D., Tanaka, M., Matsuzaki, T., Izumo, K., Nakano, N., Matsuura, E., Saito, M., Nagai, M., Horiuchi, M., Utsunomiya, A., et al. (2020) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0008361 · Cited by 8
Corticosteroids for viral central nervous system infections
Bodilsen, J., Duerlund, L. S., & Nielsen, H. (2025) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000001106 · Cited by 7
Meyerowitz, E. A., Mukerji, S. S., Harrold, G. K., Erdil, R. M., Chen, S. T., Rudmann, E. A., Tsibris, A. M. N., Venna, N., & Robbins, G. K. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad281 · Cited by 7
HTLV-1c associated bronchiolitis in an Aboriginal man from central Australia
Chiong, F. J. K., Jersmann, H. P. A., Wilson, K. M., & Einsiedel, L. J. (2020) · IDCases · doi:10.1016/j.idcr.2020.e00714 · Cited by 7
Seervai, R. N. H., Friske, S. K., Chu, E. Y., Phillips, R. M., Nelson, K. C., Huen, A., Cho, W. C., Aung, P. P., Torres-Cabala, C. A., Prieto, V. G., et al. (2022) · Journal of Cutaneous Pathology · doi:10.1111/cup.14327 · Cited by 6
Hasheminia, A., Mann, S., Liblik, K., & El-Diasty, M. M. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05550-9 · Cited by 6
Noori, B., Shahbahrami, R., Douzandegan, Y., Mozhgani, S., Norouzi, M., & Jazayeri, S. M. (2026) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/cjid/8667755 · Cited by 6
Cao, P., Yang, M., Chang, C. C.-C., Wu, H., & Lu, Q. (2022) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-022-08936-y · Cited by 6
Non-cancerous complications in HTLV-1 carriers
Ohmoto, A., & Fuji, S. (2024) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2024.2336547 · Cited by 5
Ohmoto, A., Fuji, S., Kohmo, S., & Katsura, K. (2022) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2151437 · Cited by 5
Virus-induced RGMa expression drives neurodegeneration in HTLV-1–associated myelopathy
Araya, N., Yamagishi, M., Nakashima, M., Asahara, N., Kiyohara, K., Aratani, S., Yagishita, N., Horibe, E., Izumi, I., Watanabe, T., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.184530 · Cited by 5
Self-citationMyelopathy secondary to human T-lymphotropic virus and Treponema pallidum infection: case report
Enríquez-Ruano, P., Navarro, C. E., Ariza-Varón, M., & Calderón-Castro, A. D. P. (2019) · Spinal Cord Series and Cases · doi:10.1038/s41394-019-0238-0 · Cited by 5
Nakaya, Y., Yoshida, M., Tsutsumi, M., Fuseya, H., Horiuchi, M., Yoshimura, T., Hayashi, Y., Nakao, T., Koh, K., Niino, D., et al. (2019) · Journal of the Japan Society of the Reticuloendothelial System · doi:10.3960/jslrt.19010 · Cited by 5
Human T-cell leukemia virus type 1: oncogenic potential and vaccine development strategies
Vásconez-González, J., Suárez-Sangucho, I. A., Acosta-Muñoz, E., y Miño, L. P., Borja-Mendoza, D. A., Alexander-Castillo, J. A., Saa, J., Salazar-Calvopiña, N., Cárdenas, P., López‐Cortés, A., et al. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1587802 · Cited by 4
Repurposing of Chemokine Antagonists for Combined Phase‐Resolved Spinal Cord Injury Treatment
Belogurov, A. A., Telegin, G. B., Чернов, А. С., Kudriaeva, A. A., Minakov, A. N., Rodionov, M. V., Kazakov, V. A., Паликов, В. А., Poluektov, Y. M., Ziganshin, R., et al. (2025) · Advanced Science · doi:10.1002/advs.202516569 · Cited by 4
CRISPR Targeting the Integrated HTLV-1 Virus
Wilkie, T., & Panfil, A. R. (2022) · Springer eBooks · doi:10.1007/978-3-030-93333-3_6 · Cited by 4
de Wolf, A. C. M. T., Herberts, C. A., & Hoefnagel, M. H. N. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00091 · Cited by 4
Iordan, I., Onisâi, M., Vlădăreanu, A., Mambet, C., Marinescu, C., Nistor, R. I., & Bumbea, H. (2022) · Medicina · doi:10.3390/medicina58111553 · Cited by 4
Laboratory Diagnosis of HTLV-1-Associated Myelopathy
Rolon, R. M. M., & Yao, J. D. C. (2020) · Clinical Microbiology Newsletter · doi:10.1016/j.clinmicnews.2020.07.004 · Cited by 4
Anand, P. (2021) · Seminars in Neurology · doi:10.1055/s-0041-1725126 · Cited by 4
Efficacy of l ‐Arginine treatment in patients with HTLV‐1‐associated neurological disease
Nozuma, S., Matsuura, E., Tashiro, Y., Nagata, R., Ando, M., Hiramatsu, Y., Higuchi, Y., Sakiyama, Y., Hashiguchi, A., Michizono, K., et al. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51715 · Cited by 4
Self-citationShimizu, Y., Koyasu, S., Suzukida, M., Izumi, K., Kidera, E., Shindo, T., Saga, T., Ono, M., Takaori‐Kondo, A., & Nakamoto, Y. (2022) · Annals of Nuclear Medicine · doi:10.1007/s12149-021-01706-4 · Cited by 4
Nakashima, M., Nagai, K., Takao, N., Araya, N., Kuze, Y., Mizuike, J., Tosaka, S., Aratani, S., Yagishita, N., Horibe, E., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64836-7 · Cited by 4
Self-citationTargeted immunotherapy for HTLV-1-associated myelopathy: a step in the right direction
Davies, N. W. S., & Taylor, G. P. (2023) · Brain · doi:10.1093/brain/awad229 · Cited by 3
Nakashima, M., & Yamano, Y. (2025) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.70001 · Cited by 3
Self-citationJozan, N. G., Vahidi, Z., Rafatpanah, H., Boostani, R., Zemorshidi, F., Sahraian, M. A., Tabeshpour, J., Baghaei, M., & Nahayati, M. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13134-9 · Cited by 3
Nozuma, S., Matsuzaki, T., Tanaka, M., Kodama, D., Dozono, M., Yoshida, T., Takashima, H., & Kubota, R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041706 · Cited by 3
Adult T-Cell Leukemia-Lymphoma Presenting Concurrently with Myelopathy
Poondru, S., Joseph, A., Harding, J. C., Sundaramoorthi, H., Mehta–Shah, N., Green, P. A., Hassan, A., Rauch, D. A., & Ratner, L. (2022) · Case Reports in Oncology · doi:10.1159/000525174 · Cited by 3
Spontaneous regression in mature T-cell non-Hodgkin lymphoma
Ohmoto, A., & Fuji, S. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2439469 · Cited by 3
CRISPR-Cas-Based Gene Therapy to Target Viral Infections
Hussein, M., Berkhout, B., & Herrera-Carrillo, E. (2022) · Springer eBooks · doi:10.1007/978-3-030-93333-3_5 · Cited by 2
Pang, G., Wang, R., Yang, H., Chai, M., Gao, Y., Chen, S., Mao, T., Du, L., Lan, Y., Li, S., et al. (2025) · Protein Science · doi:10.1002/pro.70090 · Cited by 2
Human T-Cell Lymphotropic Virus
(2011) · Springer eBooks · doi:10.1007/978-3-642-16483-5_6414 · Cited by 2
Keener, A. B. (2018) · Nature Medicine · doi:10.1038/s41591-018-0245-x · Cited by 2
Yamano, Y. (2019) · Uirusu · doi:10.2222/jsv.69.29 · Cited by 2
Self-citationNakashima, T., Kusumoto, S., Ishida, T., Kato, C., Hagiwara, S., Narita, T., Masaki, A., Ito, A., Ri, M., Komatsu, H., et al. (2024) · Hepatology Research · doi:10.1111/hepr.14057 · Cited by 2
Expanding the neurological spectrum of HTLV-1 beyond HAM/TSP: a contemporary perspective
Araujo, A. Q. C., & Silva, M. T. T. (2025) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2025.101347 · Cited by 1
De, S. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-13312-1.00005-2 · Cited by 1
Mycophenolate Mofetil for the Long-Term Treatment of Htlv-1 Associated Myelopathy
Sanz, M., Chernet, S., Shymansky, J., Mandel, A., Chitrakar, A., Kaminski, H. J., Ghosh, P., & Soriano-Sarabia, N. (2024) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2024.578294 · Cited by 1
Use of Oral Corticosteroids to Treat HTLV-1-Associated Myelopathy (HAM) in São Paulo, Brazil
Dahy, F. E., Assone, T., Marcusso, R. M. N., de Moura, J. V. L., Haziot, M. E., Vidal, J. E., Smid, J., de Oliveira, A. C. P., & Casseb, J. (2023) · Microbiology Research · doi:10.3390/microbiolres14020046 · Cited by 1
Unmasking HAM/TSP: understanding HTLV-1-driven neurological disease
Letafati, A., Tajik, S., Rad, M. V., Shahbahrami, R., Moulaeian, M., Norouzi, M., & Mozhgani, S. (2026) · Journal of NeuroVirology · doi:10.1007/s13365-026-01305-x · Cited by 1
Morrison, A., Samudralwar, R. D., & Berger, J. R. (2026) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200570 · Cited by 1
HTLV-1-associated myelopathy as a translational model of progressive neurodegeneration
Silva, M. T. T., & Araujo, A. Q. C. (2026) · Brain · doi:10.1093/brain/awag121 · Cited by 1
Infectious leukoencephalopathies
Jakabek, D., Chaganti, J. R., & Brew, B. J. (2024) · Handbook of clinical neurology · doi:10.1016/b978-0-323-99209-1.00016-8 · Cited by 1
久保田, 龍. (2024) · Skin Cancer · doi:10.5227/skincancer.39.120 · Cited by 1
Mahdifar, M., Boostani, R., Taylor, G. P., Rezaee, S. A., & Rafatpanah, H. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-03999-8 · Cited by 1
Sato, T., & Yamano, Y. (2018) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12467
Self-citation山野嘉久 (2020) · doi:10.34397/jsnd.25.1_87
Manifestazioni neurologiche legate all’“human T-cell leukemia/lymphoma virus” tipo 1 (HTLV-1)
Olindo, S., Jeannin, S., & Lézin, A. (2021) · EMC - Neurologia · doi:10.1016/s1634-7072(21)44999-8
HTLV-1: A View from the Rheumatologist
Fuentes, A., & Burgos, P. I. (2019) · Springer eBooks · doi:10.1007/978-3-030-23311-2_16
METHYLATION CONCEPTS OF HTLV-1 THROUGH EPIGENETIC MECHANISM- A SYNOPTIC REVIEW
Venkatesh, S., Mohanty, S. R., Pal, V. S., Sharma, H., Mathpal, S., & Yadav, N. S. (2020) · International Journal of Engineering Applied Sciences and Technology · doi:10.33564/ijeast.2020.v05i08.029
Clinical Reasoning: Leg weakness and stiffness at the emergency room
af Edholm, K., Lidman, C., Andersson, S., Solders, G., & Paucar, M. (2019) · Neurology · doi:10.1212/wnl.0000000000006885
Metadata
- Authors
- Sato, T., Coler-Reilly, A. L. G., Yagishita, N., Araya, N., Inoue, E., Furuta, R., Watanabe, T., Uchimaru, K., Matsuoka, M., Matsumoto, N., Hasegawa, Y., & Yamano, Y.
- Affiliations
- St. Marianna University School of Medicine (JP)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-02-08
- Volume
- 378
- Issue
- 6
- Pages
- 529-538
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2787149056
- Cited by
- 113
- References
- 33
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 15 · 2023: 10 · 2022: 15 · 2021: 13 · 2020: 19 · 2019: 13 · 2018: 4
- FWCI
- 5.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ministry of Health Labour and Welfare
- Japan Agency for Medical Research and Development (17ek0109083)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Health Sciences › Medicine › Surgery › Cervical and Thoracic Myelopathy
- Keywords
- mogamulizumab, anti-CCR4 monoclonal antibody, HTLV-1-associated myelopathy/tropical spastic paraparesis, HAM/TSP, adult T-cell leukemia/lymphoma, proviral load, myelitis, neuroinflammation, CXCL10, pharmacokinetics, safety
- MeSH terms
- Adult, Aged, Antineoplastic Agents, Dose-Response Relationship, Drug, Drug Administration Schedule, Exanthema, Female, Humans, Male, Middle Aged, T-Lymphocytes, Human T-lymphotropic virus 1, Paraparesis, Tropical Spastic, Area Under Curve, Viral Load, Receptors, CCR4, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.